Search Media Items

Skin cancer screening may be done by visual inspection, either by oneself or a clinician, but has not been shown to reduce mortality from skin cancer. Get detailed information about skin cancer risk factors and the benefits and harms of screening for it in this summary for clinicians.

Breast cancer screening most often includes mammography but can also include ultrasound, MRI, and other tests. Get detailed information about the potential benefits and harms of the tests used to screen for breast cancer in this summary for clinicians.

Oral cavity, pharyngeal, and laryngeal cancer screening is not recommended as part of routine cancer screening. Get detailed information about screening, including the potential benefits and harms of screening for these cancers in this summary for clinicians.

Colorectal cancer (CRC) screening reduces CRC mortality; some screening modalities also reduce CRC incidence. Get detailed information about CRC screening tests (e.g., fecal occult blood test, sigmoidoscopy, colonoscopy, stool DNA) including potential benefits and harms in this clinician summary.

For testicular cancer, there is no standard or routine screening test. Review the limited evidence on the benefits and harms of screening for testicular cancer using ultrasound, physical examination, and self-examination in this expert-reviewed summary.

Prostate cancer screening with the prostate-specific antigen (PSA) test or digital rectal exams has not been shown to reduce prostate cancer deaths. Get detailed information about prostate cancer screening, including potential benefits and harms, in this summary for clinicians.

Cervical cancer screening tests (e.g., the Papanicolaou (Pap) Test, HPV DNA, Thin-prep) reduce mortality from cervical cancer. Get detailed information about the evidence behind, and the potential benefits and harms of cervical cancer screening in this summary for clinicians.

For stomach (gastric) cancer, there is no standard or routine screening test for the general U.S. population. Review the evidence on the benefits and harms of screening for gastric cancer using barium-meal photofluorography, gastric endoscopy, or serum pepsinogen in this expert-reviewed summary.

Cancer screening can reduce some cancer mortality and morbidity, but potential harms must be weighed against any potential benefits. Get detailed, peer-reviewed and evidence-based information about cancer screening in this overview for clinicians.

Ovarian, fallopian tube, and primary peritoneal cancer screening is not currently recommended as part of routine cancer screening. Get detailed information about the potential benefits and harms of screening tests used in these cancers in this summary for clinicians.

Neuroblastoma screening, according to solid evidence, does not lead to decreased mortality and exposes infants to potential serious harms. Get detailed information about neuroblastoma and the potential benefits and harms of screening in this summary for clinicians.

Endometrial cancer screening by ultrasonography or tissue sampling is not supported by current evidence, but most cases are diagnosed at early stage. Get detailed information about potential harms of endometrial cancer screening in this summary for clinicians.

Lung cancer screening with low-dose spiral CT scans has been shown to decrease the risk of dying from lung cancer in heavy smokers. Screening with chest x-ray or sputum cytology does not reduce lung cancer mortality. Get detailed information about lung cancer screening in this clinician summary.

Liver (hepatocellular) cancer screening, even in high risk individuals, has not been shown to be beneficial. Get detailed information about liver cancer screening, potential screening modalities, and research directions in this summary for clinicians.

Neuroblastoma screening does reduce the chance of dying from the disease. Not all screening tests are helpful and most have risks. Learn more about neuroblastoma and the potential benefits and harms of screening in this expert-reviewed summary.